

Jun Lu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5910057/publications.pdf>

Version: 2024-02-01

61
papers

1,021
citations

430442

18
h-index

525886

27
g-index

64
all docs

64
docs citations

64
times ranked

1519
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrative epigenomic analysis reveals unique epigenetic signatures involved in unipotency of mouse female germline stem cells. <i>Genome Biology</i> , 2016, 17, 162.	3.8	61
2	Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy. <i>European Respiratory Journal</i> , 2019, 53, 1801562.	3.1	61
3	Genome-Wide Plasma Cell-Free DNA Methylation Profiling Identifies Potential Biomarkers for Lung Cancer. <i>Disease Markers</i> , 2019, 2019, 1-7.	0.6	44
4	Association between body mass index and diabetic retinopathy in Chinese patients with type 2 diabetes. <i>Acta Diabetologica</i> , 2015, 52, 701-708.	1.2	41
5	Preventive effect of a galactoglucomannan (GGM) from <i>Dendrobium huoshanense</i> on selenium-induced liver injury and fibrosis in rats. <i>Experimental and Toxicologic Pathology</i> , 2012, 64, 899-904.	2.1	40
6	Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. <i>International Journal of Cancer</i> , 2020, 146, 3124-3133.	2.3	40
7	Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. <i>Toxicology Letters</i> , 2016, 258, 227-236.	0.4	34
8	Maternal Gestational Diabetes Is Associated With Offspring's Hypertension. <i>American Journal of Hypertension</i> , 2019, 32, 335-342.	1.0	34
9	Circulating DNA-Based Sequencing Guided Anlotinib Therapy in Non-Small Cell Lung Cancer. <i>Advanced Science</i> , 2019, 6, 1900721.	5.6	30
10	A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab. <i>Oncolmmunology</i> , 2020, 9, 1731072.	2.1	30
11	hsa_circ_0003222 accelerates stemness and progression of non-small cell lung cancer by sponging miR-527. <i>Cell Death and Disease</i> , 2021, 12, 807.	2.7	29
12	Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells. <i>BMC Medical Genomics</i> , 2019, 12, 38.	0.7	28
13	<i>Mycobacterium tuberculosis</i> antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDL-1 signaling pathway. <i>Cell Death and Disease</i> , 2019, 10, 44.	2.7	27
14	Associations between clinical characteristics and chronic complications in latent autoimmune diabetes in adults and type 2 diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 411-420.	1.7	25
15	Different characteristics and survival in non-small cell lung cancer patients with primary and acquired EGFR T790M mutation. <i>International Journal of Cancer</i> , 2019, 144, 2880-2886.	2.3	25
16	CCAAT/Enhancer-Binding Protein β Is a Crucial Regulator of Human Fat Mass and Obesity Associated Gene Transcription and Expression. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	24
17	Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2017, 8, 619-625.	1.1	24
18	Temporal requirements for ISL1 in sympathetic neuron proliferation, differentiation, and diversification. <i>Cell Death and Disease</i> , 2018, 9, 247.	2.7	23

#	ARTICLE	IF	CITATIONS
19	Daily Branched-Chain Amino Acid Intake and Risks of Obesity and Insulin Resistance in Children: A Cross-Sectional Study. <i>Obesity</i> , 2020, 28, 1310-1316.	1.5	23
20	Integrated Transcriptome Analysis Reveals KLK5 and L1CAM Predict Response to Anlotinib in NSCLC at 3rd Line. <i>Frontiers in Oncology</i> , 2019, 9, 886.	1.3	20
21	Serum Magnesium Concentration Is Inversely Associated with Albuminuria and Retinopathy among Patients with Diabetes. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-6.	1.0	19
22	Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas. <i>Cancer</i> , 2018, 124, 2399-2406.	2.0	19
23	Chromatin accessibility analysis reveals that TFAP2A promotes angiogenesis in acquired resistance to anlotinib in lung cancer cells. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1357-1365.	2.8	19
24	Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy. <i>Technology in Cancer Research and Treatment</i> , 2018, 17, 153303381880180.	0.8	18
25	Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial. <i>Cancer Biology and Medicine</i> , 2021, 18, 816-824.	1.4	18
26	Epigenetic Profiling of H3K4Me3 Reveals Herbal Medicine Jinfukang-Induced Epigenetic Alteration Is Involved in Anti-Lung Cancer Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2016, 2016, 1-13.	0.5	16
27	Beneficial effect of PEDF-transfected ADSCs on erectile dysfunction in a streptozotocin-diabetic rat model. <i>Cell and Tissue Research</i> , 2016, 366, 623-637.	1.5	16
28	Pancreatic volume is reduced in patients with latent autoimmune diabetes in adults. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 858-866.	1.7	15
29	Jinfukang induces cellular apoptosis through activation of Fas and DR4 in A549 cells. <i>Oncology Letters</i> , 2018, 16, 4343-4352.	0.8	15
30	Cigarette Smoking Is Associated with a Lower Prevalence of Newly Diagnosed Diabetes Screened by OGTT than Non-Smoking in Chinese Men with Normal Weight. <i>PLoS ONE</i> , 2016, 11, e0149234.	1.1	15
31	Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?. <i>Lung Cancer</i> , 2018, 117, 27-31.	0.9	13
32	Chemotherapy Plus EGFR-TKI as First-Line Treatment Provides Better Survival for Advanced EGFR-Positive Lung Adenocarcinoma Patients: Updated Data and Exploratory In Vitro Study. <i>Targeted Oncology</i> , 2020, 15, 175-184.	1.7	13
33	CXCL9 as a Prognostic Inflammatory Marker in Early-Stage Lung Adenocarcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1049.	1.3	13
34	Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. <i>Cell Death and Disease</i> , 2021, 12, 170.	2.7	13
35	DUBR suppresses migration and invasion of human lung adenocarcinoma cells via ZBTB11-mediated inhibition of oxidative phosphorylation. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 157-166.	2.8	13
36	Herbal formula Yangyinjiedu induces lung cancer cell apoptosis via activation of early growth response 1. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 6193-6202.	1.6	12

#	ARTICLE	IF	CITATIONS
37	Adjuvant Chemotherapy Candidates in Stage I Lung Adenocarcinomas Following Complete Lobectomy. <i>Annals of Surgical Oncology</i> , 2019, 26, 2392-2400.	0.7	12
38	TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 732125.	2.2	10
39	Prognostic and Predictive Value of Blood Tumor Mutational Burden in Patients With Lung Cancer Treated With Docetaxel. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 582-589.	2.3	10
40	Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring <i>STK11</i> or <i>KEAP1</i> mutation. <i>Oncolmmunology</i> , 2021, 10, 1865670.	2.1	9
41	ctDNA-Profilng-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients. <i>Frontiers in Genetics</i> , 2021, 12, 723670.	1.1	9
42	Genome-Wide Profiling Reveals That Herbal Medicine Jinfukang-Induced Polyadenylation Alteration Is Involved in Anti-Lung Cancer Activity. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-8.	0.5	8
43	The clinicopathological and molecular characteristics of resected <i>EGFR</i> mutant lung adenocarcinoma. <i>Cancer Medicine</i> , 2022, 11, 1299-1309.	1.3	6
44	Local consolidative therapy for synchronous oligometastatic non-small cell lung cancer treated with first-line pembrolizumab: A retrospective observational study. <i>Thoracic Cancer</i> , 2022, , .	0.8	6
45	Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired <i>EGFR</i> T790M mutation. <i>Respiratory Research</i> , 2021, 22, 145.	1.4	5
46	Equivalent efficacy assessment of QL1101 and bevacizumab in nonsquamous non-small cell lung cancer patients: A two-year follow-up data update. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2022, 34, 28-39.	0.7	5
47	Glucose metabolism among obese and non-obese children of mothers with gestational diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e000822.	1.2	4
48	The centromere-associated protein CENPU promotes cell proliferation, migration, and invasiveness in lung adenocarcinoma. <i>Cancer Letters</i> , 2022, 532, 215599.	3.2	4
49	Effect and outcomes analysis of anlotinib in non-small cell lung cancer patients with liver metastasis: results from the ALTER 0303 phase 3 randomized clinical trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 1417-1424.	1.2	4
50	Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer. <i>Asian Journal of Andrology</i> , 2008, 10, 883-889.	0.8	3
51	PLGF knockdown attenuates hypoxia-induced stimulation of cell proliferation and glycolysis of lung adenocarcinoma through inhibiting Wnt/ β -catenin pathway. <i>Cancer Cell International</i> , 2021, 21, 18.	1.8	3
52	Comparative Study of Pulmonary Combined Large-Cell Neuroendocrine Carcinoma and Combined Small-Cell Carcinoma in Surgically Resected High-Grade Neuroendocrine Tumors of the Lung. <i>Frontiers in Oncology</i> , 2021, 11, 714549.	1.3	3
53	Different Characteristics and Survival between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5666-5678.	0.7	3
54	Characteristics and Response to Crizotinib in ALK-Rearranged, Advanced Non-Adenocarcinoma, Non-Small Cell Lung Cancer (NA-NSCLC) Patients: a Retrospective Study and Literature Review. <i>Targeted Oncology</i> , 2018, 13, 631-639.	1.7	2

#	ARTICLE	IF	CITATIONS
55	Application value of thromboelastography in perioperative clinical blood transfusion and its effect on the outcome of patient. <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 3483-3488.	0.8	2
56	The Survival Benefit for Optimal Glycemic Control in Advanced Non-Small Cell Lung Cancer Patients With Preexisting Diabetes Mellitus. <i>Frontiers in Oncology</i> , 2021, 11, 745150.	1.3	2
57	The temporal requirements for Isl1 in sympathetic neuron proliferation, differentiation and diversification. <i>Mechanisms of Development</i> , 2017, 145, S125.	1.7	0
58	Daily Branch Chained Amino Acid Intake and the Risks of Obesity and Insulin Resistance in Children. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa061_072.	0.1	0
59	Association Between Obesity and Poor Prognosis in Patients Receiving Anlotinib for Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2022, 13, 812555.	1.6	0
60	Multi-Omics Signatures Identification for LUAD Prognosis Prediction Model Based on the Integrative Analysis of Immune and Hypoxia Signals. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 840466.	1.8	0
61	ASO Visual Abstract: Different Characteristics and Survival Between Surgically Resected Pure and Combined Pulmonary Large Cell Neuroendocrine Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0